Treatment with a combination of oral paclitaxel and encequidar led to higher and stronger response rates compared with standard paclitaxel intravenous therapy in women with metastatic breast cancer, topline data from a Phase 3 trial shows. Paclitaxel is a widely used chemotherapy agent that interferes with the molecular components of cells' internal skeletons, which are required during cell division. It effectively prevents cancer cells from dividing and growing. The medication is normally given intravenously, or into the vein, because its absorption is very poor when administered orally. However, when oral placlitaxel is given together with enciquidar — a compound Athenex discovered as part of its Orascovery Platform — the body's ability to absorb the chemotherapy agent increases dramatically. In fact, the combination has been found to achieve values identical to those obtained for paclitaxel's intravenous formulation. A multicenter, open-label, randomized, Phase 3 trial (NCT02594371) — sponsored by Athenex — is currently comparing the safety and efficacy of the combination therapy of oral paclitaxel and encequidar to that of intravenous paclitaxel in the treatment of women with metastatic breast cancer. It enrolled a total 402 women who randomly received either the combination therapy — collectively called Oral Paclitaxel — or intravenous (into-the-blood) paclitaxel.